You are here

Once a day nilotinib: A Real Life Observational Study

session: 632. Chronic Myeloid Leukemia: Therapy: Treatment Discontinuation, Dose Reduction, and Prognostic IndicatorsSunday, December 10, 2017: 8:45 AMBldg A, Lvl 4, Marcus Aud. (Georgia World Congress Center)


Delphine Rea, MD1, Jean-Michel Cayuela, PhD2*, Stephanie Dulucq, PhD3* and Gabriel Etienne, MD, PhD4*

The standard dosing regimen for the BCR-ABL1 tyrosine kinase inhibitor (TKI) nilotinib in chronic myeloid leukaemia (CML) is 300mg twice daily (BID) in the frontline setting and 400mg BID in the 2nd line setting or beyond. Patients (pts) are instructed to fast within 2 hours before and 1 hour after medication intake due to significant high-fat food effects on drug bioavailability. On-label dose adjustments to a lower-dose once-daily (QD) regimen are recommended solely in case of significant toxicity